Company record · updated August 5, 2026
KWOL Intermediate, Inc (Worldwide Clinical Trials): 2 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs December 31, 2024 to December 31, 2025.
2observations
2source filings
2verified rows
2025-12-31most recent as-of date
Source rails for this company: BDC equity mark (2).
Reported by 1 filer: Nuveen Churchill Private Capital Income Fund.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2025-12-31 | price per share | 1,040.8163 USD | Nuveen Churchill Private Capital Income Fund | VERIFIED | Series A Preferred Shares: 49 units / fair value 51 (declared thousands) | 0001911066-26-000012 |
| 2024-12-31 | price per share | 1,040.8163 USD | Nuveen Churchill Private Capital Income Fund | VERIFIED | Series A Preferred Shares: 49 units / fair value 51 (declared thousands) | 0001628280-25-010237 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.